Radiographic response rates in 49 evaluable patients were 12.0% and 8.3% in the HPV-positive and HPV-negative cohorts, respectively. Thirty-eight patients were reported as undergoing complete surgical resection, 10 had a planned post-nivolumab biopsy instead of definitive surgery due to a protocol misinterpretation, and four did not undergo surgery or biopsy, including two with tumor progression.
No patient had a protocol-defined TRAE-related surgical delay (>4 weeks). Any-grade treatment-related AEs (TRAEs) occurred in 19 patients (73.1%) and 14 patients (53.8%) in the HPV-positive and HPV-negative cohorts, respectively grade 3–4 TRAEs occurred in five (19.2%) and three patients (11.5%), respectively. Results From November 2015 to December 2017, 52 patients with AJCC (seventh edition) stage III–IV resectable HNSCC received neoadjuvant nivolumab (26 HPV-positive, 26 HPV-negative). 11 Bristol Myers Squibb, Princeton, New Jersey, USA.10 Department of Medical Oncology, Université de Paris, Saint Louis Hospital, Paris, France.9 Department of Medical Oncology, University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands.Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA 8 Department of Head and Neck-Endocrine Oncology, H.
0 kommentar(er)
